Group 1 - The company participated in a centralized procurement program in Xinjiang, aiming to select its gadobutrol injection and gadopentetate dimeglumine injection [1] - The proposed price for gadopentetate dimeglumine injection (15ml:7.04g) is 80.26 yuan per unit, while gadobutrol injection (15ml:7.935g) is priced at 185.69 yuan per unit [1] - For the year 2024, the sales revenue from gadopentetate dimeglumine injection is projected to be 236 million yuan, accounting for 24.01% of the company's total revenue for the period [1]

股票代码：300016 股票简称：北陆药业 公告编号：2025-060 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于钆贝葡胺注射剂、钆喷酸葡胺注射剂拟中选新疆维吾尔自治区 二十六省联盟药品集中带量采购的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，北京北陆药业股份有限公司（以下简称"公司"）参加了新疆维吾 尔自治区二十六省联盟药品集中带量采购工作，根据新疆维吾尔自治区医疗保 障局发布的《二十六省联盟药品集中带量采购综合评审拟中选结果公示》显示， 公司钆贝葡胺注射剂、钆喷酸葡胺注射剂拟中选本次集中带量采购。现将相关 情况公告如下： | 拟中选企 | 药品通用名 | 剂型 | 适应症 | 规格 | 计价 | 拟中选价 | | --- | --- | --- | --- | --- | --- | --- | | 业 | | | | | 单位 | 格（元） | | 北京北陆药 | 钆贝葡胺 | 注射剂 | 核磁共振 | 15ml:7.935g 钆贝葡胺(相当于钆 | 支 | 185.69 | | 业股份有限 | | | 增 ...

Group 1 - The company plans to dispose of up to 3 million shares of Beijing Beilu Pharmaceutical Co., Ltd. through Shenzhen Stock Exchange within three months after the pre-disclosure announcement of the reduction plan [1][2] - The company has completed the disposal of 2,998,800 shares of Beilu Pharmaceutical from March 24, 2025, to June 19, 2025, at an average transaction price of 7.46 yuan per share, totaling a transaction amount of 22,364,330 yuan [1][2] Group 2 - After the disposal, the company still holds 37,465,700 shares of Beilu Pharmaceutical, which represents a significant portion of its holdings [2] - The transaction is expected to enhance the company's asset liquidity and efficiency, allowing it to focus resources on core business development, with an estimated net profit increase of approximately 12.25 million yuan after deducting costs and related transaction taxes [2]

北陆药业（300016）公告，持股5%以上的股东三峡油漆减持股份计划已实施完毕。三峡油漆通过集中 竞价交易累计减持299.88万股公司股份，占公司总股本的0.60%。减持期间为2025年3月25日至2025年6 月19日，减持均价在6.72元/股至8.72元/股之间。减持后，三峡油漆持有公司股份从4046.45万股减少至 3746.57万股，占公司总股本比例从8.23%下降至7.59%。此次减持不会导致公司控制权发生变更，不会 对公司治理结构及持续经营产生影响。 ...

1 股票代码：300016 股票简称：北陆药业 公告编号：2025-059 债券代码：123082 债券简称：北陆转债 北京北陆药业股份有限公司 关于持股5%以上股东减持股份计划实施完毕的公告 公司持股5%以上的股东重庆三峡油漆股份有限公司保证向公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 北京北陆药业股份有限公司（以下简称"公司"）于2025年2月28日在巨 潮资讯网披露了《关于持股5%以上股东、董事兼高级管理人员减持股份的预 披露公告》(公告编号：2025-014)，持有公司股份40,464,500股（占公司总股本 8.23%）的股东重庆三峡油漆股份有限公司（以下简称"三峡油漆"）计划自 公告披露之日起15个交易日后的3个月内，以集中竞价、大宗交易或两者相结 合的方式减持不超过300万股公司股份（占公司该次减持计划披露日总股本 0.61%）。 近日，公司收到三峡油漆出具的《关于股份减持计划实施完毕的告知函》。 截至本公告日，三峡油漆通过集中竞价交易方式累计减持2,998,800股公司股份， 占公司总股本的0 ...

Group 1: Company Overview - Beilu Pharmaceutical's subsidiary, Shenzhen Yiwei Medical Technology Co., Ltd., focuses on brain disease early screening, precise diagnosis, and rehabilitation training, being the only AI enterprise in China with NMPA Class III certification in both neurodegenerative and cerebrovascular diseases [1] - Yiwei Medical's core products target stroke, Alzheimer's disease, cognitive disorders, and developmental disorders in youth, providing comprehensive solutions for screening, diagnosis, and rehabilitation [1] Group 2: National Policy Support - Recent national policies have significantly supported the development of precision diagnosis for brain diseases, aiming to train 500-1000 professionals annually and establish over 2100 cognitive disorder diagnosis centers by 2025 [2] - The National Health Commission emphasizes autism screening and intervention for children, enhancing screening, diagnosis, and intervention rates [3] Group 3: Product Development - Yiwei Medical has launched three main products: - Yiwei Brain Doctor, the first AI medical software for early Alzheimer's diagnosis, with both NMPA Class III and CE certifications [5] - Yiwei Smart Brain, a one-stop AI-assisted diagnosis platform for stroke, achieving dual certification from NMPA and FDA [5] - Yiwei Digital Therapy, integrating eye-tracking and VR technology for cognitive assessment and rehabilitation [5] Group 4: Business Model - Yiwei Medical offers a full-cycle service from screening to rehabilitation, collaborating with over 200 hospitals and health institutions, and exploring diverse revenue streams [6] - The company has introduced a comprehensive "brain routine" health check package and established digital rehabilitation centers in communities [6] Group 5: Financial Performance - In 2024, Beilu Pharmaceutical's revenue from contrast agents reached CNY 58.80 million, a 9.87% increase; diabetes products generated CNY 12.60 million, up 33.24%; while raw materials saw a decline of 20.83% to CNY 9.00 million [9] - The company anticipates continued growth across its business segments in 2025 [9] Group 6: International Expansion - Beilu Pharmaceutical's overseas revenue reached CNY 13.22 million in 2024, marking a 15.02% increase, with successful product exports to South America, Africa, and Asia [11] - The company is advancing its internationalization efforts with certifications in the EU and plans for further market expansion in Southeast Asia [11]

信用等级通知书 东方金诚债跟踪评字【2025】0093 号 北京北陆药业股份有限公司： 东方金诚国际信用评估有限公司根据跟踪评级安排对贵公司及"北 陆转债"的信用状况进行了跟踪评级，经信用评级委员会评定，此 次跟踪评级维持贵公司主体信用等级为 A，评级展望为稳定，同时 维持"北陆转债"信用等级为 A。 东方金诚国际信用评估有限公司 信评委主任 二〇二五年六月十六日 东方金诚债跟踪评字【2025】0093 号 信用评级报告声明 为正确理解和使用东方金诚国际信用评估有限公司（以下简称"东方金诚"）出具的信用 评级报告（以下简称"本报告"），本公司声明如下： 1.本次评级为委托评级，东方金诚与受评对象不存在任何影响本次评级行为独立、客观、公正 的关联关系，本次项目评级人员与评级对象之间亦不存在任何影响本次评级行为独立、客观、 公正的关联关系。 2.本次评级中，东方金诚及其评级人员遵照相关法律、法规及监管部门相关要求，充分履行了 勤勉尽责和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的原则。 3.本评级报告的结论，是按照东方金诚的评级流程及评级标准做出的独立判断，未受评级对象 和第三方组织或个人的干预和影响 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Core Viewpoint - Northland Pharmaceutical Co., Ltd. has received approval from the Hungarian drug regulatory authority for the marketing authorization of Iohexol injection, which enhances the company's international market competitiveness in contrast agents [1] Company Summary - The drug approved is Iohexol 350mg I/ml injection, with the registration number OGYI-T-24580/1 [1] - The approval date is June 11, 2025, and the validity period is five years [1] - This approval supports the company's efforts to expand into overseas markets and lays a solid foundation for sustainable development in the international market for contrast agents [1]

债券代码：123082 债券简称：北陆转债 股票代码：300016 股票简称：北陆药业 公告编号：2025-058 北京北陆药业股份有限公司 关于公司碘海醇注射液匈牙利获批上市的公告 近期，北京北陆药业股份有限公司（以下简称"公司"）收到匈牙利药监 局核准签发的关于公司碘海醇注射液的《药品上市许可证书》，具体情况如下： 一、证书相关情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 持有人：北京北陆药业股份有限公司 注册号：OGYI-T-24580/01 药品名称：碘海醇 350 mg I/ml 注射液 获批日期：2025 年 6 月 11 日 有效期：5 年 签发机关：匈牙利药监局 二、对公司影响及风险提示 本次碘海醇注射液获得匈牙利药监局颁发的《药品上市许可证书》，是该 产品获批荷兰上市之后取得的又一个欧盟成员国的批准注册，有利于公司进一 步推进海外市场拓展，提升公司对比剂产品的国际市场竞争力，为国际市场的 可持续发展奠定坚实基础，未来将对公司经营产生积极影响。 1 由于医药行业的特点，相关产品在国际市场的销售情况易受到市场环境变 化、汇率波动等因素影响 ...